T<sub>1-2</sub>期鼻咽癌RTOG推荐靶区与中国推荐靶区IMRT计划之间后组颅神经NTCP差异性分析

doi:10.3760/cma.j.issn.1004-4221.2016.06.002

摘要
图/表
参考文献()
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (752 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要目的通过研究T_1-2期鼻咽癌IMRT中基于RTOG推荐靶区和中国靶区IMRT计划之间后组颅神经NTCP的差异,为鼻咽癌IMRT中后组颅神经保护提供剂量体积效应依据。方法选取2013—2015年间T₁、T₂期鼻咽癌病例共20例,分别在其CT定位影像上勾画后组颅神经。根据RTOG0225推荐方法(RTOG靶区方法)和2010年中国鼻咽癌临床分期工作委员会推荐的靶区定义方法(中国靶区方法)勾画靶区和设计治疗计划,计算两种靶区定义方法之间后组颅神经受量及NTCP差异性。结果 RTOG靶区和中国靶区方法的左、右侧后组颅神经受量D_max分别为(7450±273)、(7294±309) cGy和(7361±160)、(7190±395) cGy (左、右侧P=0.018、0.042);D_mean分别为(6735±285) 、(6660±333) cGy和(6446±429) 、(6299±467) cGy (左、右侧P=0.000、0.000);NTCP分别为(60±10)%、(57±13)%和(51±15)%、(45±17)%(左、右侧P=0.000、0.000)。结论鼻咽癌IMRT中将后组颅神经作为常规OAR来精确勾画并进行剂量评估和NTCP预测是可行的;后组颅神经的NTCP与其靶区接受剂量和受照体积密切相关;中国靶区方法的后组颅神经受量和NTCP都明显小于RTOG靶区方法。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	钱建军
	孙彦泽
	周钢
	田野
	陆雪官

关键词 ：鼻咽肿瘤/调强放射疗法, 后组颅神经, 正常组织并发症概率

Abstract：Objective To investigate the difference in normal tissue complication probability (NTCP) of lower cranial nerves (LCNs) between target volumes recommended by Radiation Therapy Oncology Group (RTOG) and China in intensity-modulated radiotherapy (IMRT) for T_1-2 nasopharyngeal carcinoma (NPC), and to provide the evidence of dose-volume effect for the protection of LCNs in IMRT for NPC. Methods A total of 20 patients with T_1-2 NPC who were treated from 2013 to 2015 were enrolled, and LCNs were delineated on CT images. Target volume delineation and treatment plan designing were performed according to the method recommended by RTOG0225(RTOG target volume delineation method) or the Chinese Working Committee for Clinical Staging of NPC in 2010(Chinese target volume delineation method), and the differences in the dose to LCNs and NTCP were calculated. Results In the RTOG and Chinese Methods for target volume delineation, D_max to the left and right LCNs was 7450±273 cGy/7294±309 cGy and 7361±160 cGy/7190±395 cGy, respectively (P=0.018 and 0.042), D_mean was 6735±285 cGy/6660±333 cGy and 6446±429 cGy/6299±467 cGy, respectively (both P=0.000), and the NTCP was 60%±10%/57%±13% and 51%±15%/45%±17%, respectively (both P=0.000). Conclusions It is feasible to precisely delineate target volume with the LCNs as a routine OAR and predict NTCP in IMRT for T_1-2 NPC. The NTCP of the LCNs is closely associated with target volume dose and irradiated volume. The dose to the LCNs and NTCP determined by the Chinese target volume delineation method are significantly lower than those determined by the RTOG method.

Key words： Nasopharynx neoplasms/intensity modulated radiotherapy Lower cranial nerves Normal tissue complication probability

收稿日期: 2015-10-23

基金资助:江苏省临床医学科技专项(BL2014040);苏州市临床重点病种诊疗技术专项(LCZX201405)

通讯作者: 陆雪官,Email:luxueguan@163.com

引用本文:

钱建军,孙彦泽,周钢等. T_1-2期鼻咽癌RTOG推荐靶区与中国推荐靶区IMRT计划之间后组颅神经NTCP差异性分析[J]. 中华放射肿瘤学杂志, 2016, 25(6): 546-551.

Qian Jianjun,Sun Yanze,Zhou Gang et al. Difference in normal tissue complication probability of lower cranial nerves between target volumes recommended by Radiation Therapy Oncology Group and China in intensity-modulated radiotherapy for T_1-2 nasopharyngeal carcinoma[J]. Chinese Journal of Radiation Oncology, 2016, 25(6): 546-551.

链接本文:

http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.issn.1004-4221.2016.06.002 或 http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2016/V25/I6/546

[1] Mourad WF,Young BM,Young R,et al. Clinical validation and applications for CT-based atlas for contouring the lower cranial nerves for head and neck cancer radiation therapy[J].Oral Oncol,2013,49(9):956-963.DOI:10.1016/j.oraloncology.2013.03.449.
[2] Lee NY,Harris J,Garden A,et al. Phase Ⅱ multi-institutional study of IMRT ± chemotherapy for nasopharyngeal Int J Radiat Oncol Biol Phys,2007,69(S3):S13-14. carcinoma (RTOG 0225):preliminary results[J].DOI:10.1016/j.ijrobp.2007.07.025.
[3] Lee NY,Zhang Q,Pfister DG,et al. Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615):a phase 2 multi-institutional trial[J].Lancet Oncol,2012,13(2):172-180.DOI:10.1016/S1470-2045(11)70303-5.
[4] 中国鼻咽癌临床分期工作委员会.2010鼻咽癌调强放疗靶区及剂量设计指引专家共识[J].中华放射肿瘤学杂志,2011,20(4):267-269.DOI:10.3760/cma.j.issn.1004-4221.2011.04.001.Committee on clinical staging of nasopharyngeal carcinoma in China. Expert consensus on target area and dose design guidelines for 2010 nasopharyngeal carcinoma patients with radiotherapy[J]Chin J Radiat Oncol,2011,20(4):267-269.DOI:10.3760/cma.j.issn.1004-4221.2011.04.001.
[5] Lin SJ,Pan JJ,Han L,et al. Nasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy:report on the 3-year outcome of a prospective series[J].Int J Radiat Oncol Biol Phys,2009,75(4):1071-1078.DOI:10.1016/j.ijrobp.2008.12.015.
[6] 潘建基,韩露,张瑜,等.鼻咽癌缩小临床靶体积调强放疗疗效探讨[J].中华放射肿瘤学杂志,2010,19(4):283-287.DOI:10.3760/cma.j.issn.1004-4221.2010.04.001.
Pan JJ,Han L,Zhang Y,et al. Impact of reducing clinical target volume on efficacy of intensity modulated radiation therapy for nasopharyngeal carcinoma[J].Chin J Radiat Oncol,2010,19(4):283-287.DOI:10.3760/cma.j.issn.1004-4221.2010.04.001.
[7] Webb S,Nahum AE.A model for calculating tumour control probability in radiotherapy including the effects of inhomogeneous distributions of dose and clonogenic cell density[J].Phys Med Biol,1993,38(6):653-666.DOI:10.1088/0031-9155/38/6/001.
[8] Burman C,Kutcher GJ,Emami B,Goiten M.Fitting of normal tissue tolerance data to an analytic function[J].Int J Radiat Oncol Biol Phys,1991,21(1):123-135.DOI:10.1016/0360-3016(91)90172-Z.
[9] Lyman JT,Wolbarst AB.Optimization of radiation therapy,Ⅲ:a method of assessing complication probabilities from dose-volume histograms[J].Int J Radiat Oncol Biol Phys,1987,13(1):103-109.DOI:10.1016/0360-3016(87)90266-5.
[10] Emami B,Lyman J,Brown A,et al. Tolerance of normal tissue to therapeutic irradiation[J].Int J Radiat Oncol Biol Phys,1991,21(1):109-122.DOI:10.1016/0360-3016(91)90171-Y.
[11] 潘建基,洪金省,张瑜.鼻咽癌常规放疗后组颅神经的剂量学研究[J].福建医科大学学报,2006,40(2):132-135.DOI:10.3969/j.issn.1672-4194.2006.02.010.
Pan JJ,Hong JS,Zhang Y.Dosimetric study of lower cranial nerve after conventional radiotherapy in patients with nasopharyngeal carcinoma[J].J Fujian Med Univ,2006,40(2):132-135.DOI:10.3969/j.issn.1672-4194.2006.02.010.
[12] Kutcher GJ,Burman C,Brewster L,et al. Histogram reduction method for calculating complication probabilities for three-dimensional treatment planning evaluations[J].Int J Radiat Oncol Biol Phys,1991,21(1):137-146.DOI:10.1016/0360-3016(91)90173-2.
[13] Kong L,Lu JJ,Liss AL,et al. Radiation-induced cranial nerve palsy:a cross-sectional study of nasopharyngeal cancer patients after definitive radiotherapy[J].Int J Radiat Oncol Biol Phys,2011,79(5):1421-1427.DOI:10.1016/j.ijrobp.2010.01.002.
[14] Rong X,Tang Y,Chen M,et al. Radiation-induced cranial neuropathy in patients with nasopharyngeal carcinoma[J].Strahlenther Onkol,2012,188(3):282-286.DOI:10.1007/s00066-011-0047-2.
[15] Bakst RL,Lee N,Pfister DG,et al. Hypofractionated dose-painting intensity modulated radiation therapy with chemotherapy for nasopharyngeal carcinoma:a prospective trial[J].Int J Radiat Oncol Biol Phys,2011,80(1):148-153.DOI:10.1016/j.ijrobp.2010.01.026.
[16] Luk YS,Shum JSF,Sze HCK,et al. Predictive factors and radiological features of radiation-induced cranial nerve palsy in patients with nasopharyngeal carcinoma following radical radiotherapy[J].Oral Oncol,2013,49(1):49-54.DOI:10.1016/j.oraloncology.2012.07.011.
[17] Lin YS,Jen YM,Lin JC,et al. Radiation-related cranial nerve palsy in patients with nasopharyngeal carcinoma[J].Cancer,2002,95(2):404-409.DOI:10.1002/cncr.10668.
[18] King AD,Leung SF,Teo P,et al. Hypoglossal nerve palsy in nasopharyngeal carcinoma[J].Head Neck,1999,21(7):614-619.DOI:10.1002/(SICI)1097-0347(199910)21:7<614::AID-HED5>3.0.CO;2-I.
[19] 孔琳,张有望,吴永如,等.鼻咽癌放射治疗后颅神经损伤影响因素研究[J].中华放射肿瘤学杂志,2005,14(1):10-14.DOI:10.3760/j.issn:1004-4221.2005.01.003.
Kong L,Zhang YW,Wu YR,et al. Radiation-induced cranial nerve palsy and its causative factors in nasopharyngeal carcinoma[J].Chin J Radiat Oncol,2005,14(1):10-14.DOI:10.3760/j.issn:1004-4221.2005.01.003.
[20] 林少俊,潘建基,韩露,等.鼻咽癌小靶区调强放疗及化疗的远期疗效分析[J].中华放射肿瘤学杂志,2013,22(5):378-382.DOI:10.3760/cma.j.issn.1004-4221.2013.05.011.
Lin SJ,Pan JJ,Han L,et al. Long-term outcome of nasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiotherapy and chemotherapy[J].Chin J Radiat Oncol,2013,22(5):378-382.DOI:10.3760/cma.j.issn.1004-4221.2013.05.011.
[21] Wu SG,Huang SJ,Zhou J,et al. Dosimetric analysis of the brachial plexus among patients with breast cancer treated with post-mastectomy radiotherapy to the ipsilateral supraclavicular area:report of 3 cases of radiation-induced brachial plexus neuropathy[J].Radiat Oncol,2014,9(1):292.DOI:10.1186/s13014-014-0292-5.
[22] 魏宝清.从鼻咽癌放疗后颅神经放射损伤探讨当前放疗技术上的问题[J].中华放射肿瘤学杂志,1994,3(3):164-168,217.Wei BQ.Radiation induced cranial neuropathy (RICN) after radiotherapy for nasopharyngeal carcinoma (NPC):Cause related to radiation technique[J].Chin J Radiat Oncol,1994,3(3):164-168,217.